These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11870257)

  • 41. Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
    Ferrero D; Pogliani EM; Rege-Cambrin G; Fava C; Mattioli G; Dellacasa C; Campa E; Perfetti P; Fumagalli M; Boccadoro M
    Haematologica; 2006 Jun; 91(6 Suppl):ECR27. PubMed ID: 16785130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
    Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
    Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
    [No Abstract]   [Full Text] [Related]  

  • 43. [Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
    Shu LL; Jiang QL; Meng FY; Yang M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1314-8. PubMed ID: 22040995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
    García-Romero MT; Durán-McKinster C; de Ocariz MS; Carrasco-Daza D; Palacios-López C; Orozco-Covarrubias L; Ruiz-Maldonado R
    Int J Dermatol; 2012 Dec; 51(12):1529-30. PubMed ID: 22486540
    [No Abstract]   [Full Text] [Related]  

  • 45. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
    Hochhaus A
    Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
    [No Abstract]   [Full Text] [Related]  

  • 46. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate.
    Kagimoto Y; Mizuashi M; Kikuchi K; Aiba S
    Int J Dermatol; 2014 Mar; 53(3):e161-2. PubMed ID: 23786260
    [No Abstract]   [Full Text] [Related]  

  • 47. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.
    Dib EG; Ifthikharuddin JJ; Scott GA; Partilo SR
    Leuk Res; 2005 Feb; 29(2):233-4. PubMed ID: 15607374
    [No Abstract]   [Full Text] [Related]  

  • 48. [A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate].
    Oku T; Waga E; Sumiyoshi T; Yoshizaki N; Kondo H; Ohira N; Takayama T; Shikishima H; Motohara T
    Nihon Shokakibyo Gakkai Zasshi; 2003 Jul; 100(7):863-7. PubMed ID: 12884763
    [No Abstract]   [Full Text] [Related]  

  • 49. Soft tissue calcification secondary to imatinib mesylate in a patient with gastrointestinal stromal tumor.
    Enck RE; Abushahin F; Bossaer JB
    J Oncol Pharm Pract; 2014 Apr; 20(2):137-40. PubMed ID: 23676509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.
    Ohyashiki K; Kuriyama Y; Nakajima A; Tauchi T; Ito Y; Miyazawa H; Kimura Y; Serizawa H; Ebihara Y
    Leukemia; 2002 Oct; 16(10):2160-1. PubMed ID: 12357373
    [No Abstract]   [Full Text] [Related]  

  • 51. [Adverse effects of imatinib mesylate].
    Isshiki I
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
    [No Abstract]   [Full Text] [Related]  

  • 52. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
    Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y
    Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imatinib mesylate-induced pseudoporphyria.
    Berghoff AT; English JC
    J Am Acad Dermatol; 2010 Jul; 63(1):e14-6. PubMed ID: 20542169
    [No Abstract]   [Full Text] [Related]  

  • 54. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
    Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
    J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
    [No Abstract]   [Full Text] [Related]  

  • 55. Hair graying and loss induced by imatinib mesylate.
    Yun SK; Song KH; Hwang SR; Kim HU; Lee NR; Park J
    J Dermatol; 2014 Jan; 41(1):107-8. PubMed ID: 24354806
    [No Abstract]   [Full Text] [Related]  

  • 56. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
    Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
    [No Abstract]   [Full Text] [Related]  

  • 57. Skin fragility and blistering with imatinib mesylate.
    Verma SM; Murphy G
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):496-8. PubMed ID: 19925597
    [No Abstract]   [Full Text] [Related]  

  • 58. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.
    Kawakami T; Kawanabe T; Soma Y
    Acta Derm Venereol; 2009; 89(3):325-6. PubMed ID: 19479144
    [No Abstract]   [Full Text] [Related]  

  • 60. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
    Tsimberidou AM; Colburn DE; Welch MA; Cortes JE; Verstovsek S; O'Brien SM; Albitar M; Kantarjian HM; Giles FJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):229-34. PubMed ID: 12783207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.